41049-53-0

Basic information

• Product Name: 1-PHENYL-CYCLOPROPYLAMINE
• Synonyms: CHEMBRDG-BB 4102430;1-PHENYLCYCLOPROPANAMINE;1-PHENYL-CYCLOPROPYLAMINE;Cyclopropanamine, 1-phenyl-;(1-phenylcyclopropyl)amine(SALTDATA: 0.85HCl 0.3H2O);1-Phenylcyclopropan-1-amine;1-phenyl-1-cyclopropanamine hydrochloride;1-Phenylcyclopropanamine, >=95%
• CAS NO: 41049-53-0
• Molecular Formula: C₉H₁₁N
• Molecular Weight: 133.19
• Product Categories: Aminomethyl's;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 41049-53-0.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 211.4 °C at 760 mmHg
• Flash Point: 85.5 °C
• Appearance: /
• Density: 1.079 g/cm³
• Vapor Pressure: 0.183mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.78±0.20(Predicted)
• CAS DataBase Reference: 1-PHENYL-CYCLOPROPYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PHENYL-CYCLOPROPYLAMINE(41049-53-0)
• EPA Substance Registry System: 1-PHENYL-CYCLOPROPYLAMINE(41049-53-0)

Safety Data

• Hazardous Substances Data: 41049-53-0(Hazardous Substances Data)

Usage

General Description

1-Phenyl-cyclopropylamine, also known as PCA, is a chemical compound with the molecular formula C9H11N. It is a cyclopropylamine derivative that contains a phenyl group, making it a primary aromatic amine. PCA is commonly used as a building block in organic synthesis and pharmaceutical research, particularly in the development of new medications. It is known for its potential as a potent serotonin releaser and reuptake inhibitor, which has led to studies on its potential use in treating depression and other psychiatric disorders. PCA is also used in the production of other chemicals, such as dyes and pharmaceuticals, due to its versatile reactivity and potential therapeutic effects. However, it is important to handle PCA with caution, as it can be toxic and must be used in controlled laboratory settings.

InChI:InChI=1/C9H11N/c10-9(6-7-9)8-4-2-1-3-5-8/h1-5H,6-7,10H2

Upstream product

• 223513-67-5 N-(1-phenyl-cyclopropyl)-acetamide 
• 6120-95-2 1-phenyl-1-cyclopropane carboxylic acid 
• 557-20-0 diethylzinc 
• 100-47-0 benzonitrile 
• 925-90-6 ethylmagnesium bromide 
• 935-44-4 1-cyano-1-phenylcyclopropane 
• 1007-71-2 1-(1-phenyl-cyclopropyl)-ethanone 
• 140-29-4 phenylacetonitrile 
• 736055-06-4 (1-phenyl-cyclopropyl)-carbamic acid ethyl ester 

Downstream Products

• 131619-01-7 2,4-Di-tert-butyl-8-phenyl-6,7-dihydro-5-oxa-9-aza-benzocycloheptene 
• 131619-02-8 7,9-Di-tert-butyl-2-phenyl-1-aza-spiro[4.5]deca-1,7,9-trien-6-one 
• 118539-50-7 (Z)-2-(2,4-Dichloro-5-fluoro-benzoyl)-3-(1-phenyl-cyclopropylamino)-acrylic acid ethyl ester 
• 5650-34-0 2,3-epoxy-1-phenylpropan-1-one 
• 55563-72-9 3-methoxy-1-phenylpropan-1-one 
• 137596-54-4 1-Phenyl-3-(1-phenyl-cyclopropylamino)-propan-1-one 
• 137596-53-3 3,7,8,10-Tetramethyl-4a-(3-oxo-3-phenyl-propyl)-5,10-dihydro-4aH-benzo[g]pteridine-2,4-dione 
• 5650-41-9 3-hydroxy-1-phenylpropan-1-one 
• 93-55-0 1-phenyl-propan-1-one 
• 137596-55-5 C₂₃H₂₅N₅O₂ 
• 223513-67-5 N-(1-phenyl-cyclopropyl)-acetamide 
• 223513-99-3 N-(1-(4-chloromethylphenyl)cyclopropyl)acetamide 

Relevant articles and documents

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NONHODGKIN'S LYMPHOMA

The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a BTK inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor.